76153-06-5

Basic information

• Product Name: 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE
• Synonyms: 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE;5-BROMO-3-METHYL-1,2-BENZENEDIAMINE;5-Bromo-3-methyl-1,2-diaminobenzene
• CAS NO: 76153-06-5
• Molecular Formula: C₇H₉BrN₂
• Molecular Weight: 201.06
• Product Categories: pharmacetical
• Mol File: 76153-06-5.mol
• Article Data: 12

Chemical Properties

• Melting Point: 63 °C
• Boiling Point: 298.8 °C at 760 mmHg
• Flash Point: 134.5 °C
• Appearance: /
• Density: 1.589 g/cm³
• Vapor Pressure: 0.00124mmHg at 25°C
• Refractive Index: 1.67
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.31±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE(76153-06-5)
• EPA Substance Registry System: 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE(76153-06-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 76153-06-5(Hazardous Substances Data)

Usage

General Description

5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE is a chemical compound with the molecular formula C7H10BrN2. It is an aromatic amine with a bromine atom and a methyl group attached to a benzene ring, along with two amino groups at the 1 and 2 positions. 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds, and it has applications in the production of dyes and pigments. 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE may also be used in research and laboratory settings as a building block for the creation of specialized molecules with specific properties and functions. Additionally, it is important to handle this compound with care, as it may have hazardous properties and requires proper safety protocols for handling and storage.

InChI:InChI=1/C7H9BrN2/c1-4-2-5(8)3-6(9)7(4)10/h2-3H,9-10H2,1H3

Upstream product

• 570-24-1 2-Methyl-6-nitroaniline 
• 1266383-33-8 C₇H₇BrN₂O₂ 
• 120-66-1 N-(2-methylphenyl)acetamide 
• 95-53-4 o-toluidine 
• 24106-05-6 4'-bromo-2'-methylacetanilide 
• 77811-44-0 4-bromo-2-methyl-6-nitroaniline 

Downstream Products

• 187479-57-8 7‐bromo‐5‐methyl‐1,4‐dihydroquinoxaline‐2,3‐dione 
• 808745-20-2 6-bromo-2-ethoxy-4-methyl-1H-benzimidazole 
• 1162695-97-7 C₁₆H₁₃BrN₂O₂ 
• 1259015-07-0 3-bromo-1-methylphenazine 
• 255064-10-9 6-bromo-4-methyl-1H-benzo[d]imidazole 
• 532934-95-5 7‐bromo‐5‐methylquinoxaline 

Relevant articles and documents

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol as defined in the specification, or a salt thereof.

Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile

A series of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) were examined in which the pendant imidazole moiety was replaced to improve selectivity for IGF-1R inhibition over cytochrome P450 (CYP). Synthesis and SAR of these compounds is presented.